HighGravityDataInsulet — Aug 7, 2025 release
Fiscal 2025 second-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001145197-25-000037
Showing in the filing
Total Revenue Growth (Constant Currency)
“24% - 27%”
Period
FY2025
Measure
Company-defined measure
Source
Guidance table
All guidance in this release · 21
U.S. Omnipod Revenue Growth (Constant Curren… for Q3 FY2025
“21% - 24%”
U.S. Omnipod for Q3 FY2025
“21% - 24%”
International Omnipod Revenue Growth (Consta… for Q3 FY2025
“33% - 36%”
International Omnipod for Q3 FY2025
“33% - 36%”
Total Omnipod Revenue Growth (Constant Curre… for Q3 FY2025
“24% - 27%”
Total Omnipod for Q3 FY2025
“24% - 27%”
Drug Delivery Revenue Growth (Constant Curre… for Q3 FY2025
“(80)% - (75)%”
Drug Delivery for Q3 FY2025
“(80)% - (75)%”
Gross Margin for Q3 FY2025
“~71.0%”
Adjusted Operating Margin for Q3 FY2025
“17.0% - 17.5%”
Adjusted Operating Margin for FY2025
“~16.5%”
Total Revenue Growth (Constant Currency) for Q3 FY2025
“22% - 25%”
U.S. Omnipod Revenue Growth (Constant Curren… for FY2025
“22% - 25%”
U.S. Omnipod for FY2025
“22% - 25%”
International Omnipod Revenue Growth (Consta… for FY2025
“34% - 37%”
International Omnipod for FY2025
“34% - 37%”
Drug Delivery Revenue Growth (Constant Curre… for FY2025
“(30)% - (25)%”
Drug Delivery for FY2025
“(30)% - (25)%”
Total Revenue Growth (Constant Currency) for FY2025
“24% - 27%”
Total Omnipod Revenue Growth (Constant Curre… for FY2025
“25% - 28%”
Total Omnipod for FY2025
“25% - 28%”
Exhibit 99.1 · the passage around this item
… earlier in the release
11 INSULET CORPORATION NON-GAAP RECONCILIATIONS (UNAUDITED) CONTINUED REVENUE GUIDANCE Year Ending December 31, 2025 Revenue Growth GAAP Currency Impact Constant Currency U.S. Omnipod 22% - 25% —% 22% - 25% International Omnipod 37% - 40% 3% 34% - 37% Total Omnipod 26% - 29% 1% 25% - 28% Drug Delivery (30)% - (25)% —% (30)% - (25)% Total 25% - 28% 1% 24% - 27% Three Months Ended September 30, 2025 Revenue Growth GAAP Currency Impact Constant Currency U.S. Omnipod 21% - 24% —% 21% - 24% International Omnipod 36% - 39% 3% 33% - 36% Total Omnipod 25% - 28% 1% 24% - 27% Drug Delivery (80)% - (75)% —% (80)% - (75)% Total 23% - 26% 1% 22% - 25% 12
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.